- Home
- PRLD vs TARA Comparison
PRLD vs TARA Comparison
Compare PRLD & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- TARA
- Stock Information
- Founded
- PRLD 2016
- TARA N/A
- Country
- PRLD United States
- TARA United States
- Employees
- PRLD N/A
- TARA N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRLD Health Care
- TARA Health Care
- Exchange
- PRLD Nasdaq
- TARA Nasdaq
- Market Cap
- PRLD 63.3M
- TARA 52.4M
- IPO Year
- PRLD 2020
- TARA N/A
- Fundamental
- Price
- PRLD $1.04
- TARA $2.47
- Analyst Decision
- PRLD Buy
- TARA Strong Buy
- Analyst Count
- PRLD 3
- TARA 2
- Target Price
- PRLD $5.33
- TARA $24.00
- AVG Volume (30 Days)
- PRLD 408.0K
- TARA 235.4K
- Earning Date
- PRLD 11-06-2024
- TARA 11-12-2024
- Dividend Yield
- PRLD N/A
- TARA N/A
- EPS Growth
- PRLD N/A
- TARA N/A
- EPS
- PRLD N/A
- TARA N/A
- Revenue
- PRLD $3,000,000.00
- TARA N/A
- Revenue This Year
- PRLD N/A
- TARA N/A
- Revenue Next Year
- PRLD N/A
- TARA N/A
- P/E Ratio
- PRLD N/A
- TARA N/A
- Revenue Growth
- PRLD N/A
- TARA N/A
- 52 Week Low
- PRLD $1.00
- TARA $1.04
- 52 Week High
- PRLD $6.80
- TARA $5.24
- Technical
- Relative Strength Index (RSI)
- PRLD 21.69
- TARA 57.56
- Support Level
- PRLD $1.14
- TARA $2.43
- Resistance Level
- PRLD $1.36
- TARA $2.74
- Average True Range (ATR)
- PRLD 0.11
- TARA 0.19
- MACD
- PRLD 0.03
- TARA -0.00
- Stochastic Oscillator
- PRLD 7.53
- TARA 45.23
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).